Julie Zikherman, M.D.

Julie Zikherman, M.D.

Signaling Pathways in Lupus

Julie Zikherman, M.D.
University of California, San Francisco
San Francisco, California

Investigating how distinct alleles of the phosphatase CD45 differentially regulate B cell tolerance and systemic autoimmunity

Systemic lupus erythematosus (lupus) is an autoimmune disease that can result in such devastating outcomes as renal failure and death. Treatment strategies for severe lupus rely heavily on medications that are relatively non-specific and carry a heavy burden of morbid side effects. In order to generate more targeted therapies, a more refined understanding of disease progression is needed.

It has been suspected for decades that B cells must play a critical role in disease. Indeed, human and mouse genetic and biochemical studies suggest that lupus is characterized by B cells with abnormal antigen receptor signaling. (An antigen is any substance that causes the immune system to produce antibodies against it.) Most recently, novel biologic therapies targeting B cells have been approved for lupus patients. Yet the mechanisms by which abnormal signaling through the B cell antigen receptor (BCR) produces systemic autoimmune disease remain ill-defined.

Dr. Zikherman’s study using mice will define the biochemical and cellular mechanisms involved to show how abnormal BCR signaling drives lupus progression in humans. The results may suggest more effective targets for treatment.

Article Author
Arthritis National Research Foundation

The Arthritis National Research Foundation's mission is to provide initial research funding to brilliant, investigative scientists with new ideas to cure arthritis and related autoimmune diseases. Writing articles about the patients affected and the science being done to find a cure shows why we need to come together to #CureArthritis!

No Comments

Sorry, the comment form is closed at this time.